GC Biopharma reported on the 24th that its consolidated operating profit for the previous year was 32.1 billion won, a decrease of 6.8% compared to the previous year.
During the same period, sales amounted to 1.67 trillion won, an increase of 3.3% from the previous year, while net loss surged by 115.2% to 42.6 billion won.
The company pointed to the expanded losses of its subsidiary, GC Cell, as a backdrop for the poor performance. It also noted that the prolonged conflict with the government led to decreased sales in the specimen testing service sector, increased expenses related to research and development clinical trials, and impairment of goodwill recognized due to mergers. The slight increase in sales was largely influenced by exports of 'Aliglo,' an immunoglobulin blood product, to the United States.
GC Cell's consolidated sales for the previous year were 174.4 billion won, a decrease of 7.0% compared to the previous year, and it reported an operating loss of 19.9 billion won, marking a shift to a deficit. The net loss was 75.7 billion won, also reflecting a transition to a deficit.